Damien McDevitt
CEO
Aspen Neuroscience
Aspen Neuroscience develops autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy specifically for Parkinson's disease, utilizing advanced stem cell biology and genomics. This approach addresses the degeneration of neurons in patients, aiming to restore lost function and improve quality of life.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$224MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Parkinson's disease is characterized by the degeneration of neurons, leading to motor and non-motor symptoms that significantly impair a patient's quality of life. Current treatments offer symptomatic relief but do not address the underlying neuronal loss, nor do they provide a personalized approach to account for the heterogeneity of the disease.
Solution
Aspen Neuroscience is developing personalized cell therapies using autologous induced pluripotent stem cells (iPSCs) to replace neurons lost in Parkinson's disease. The company reprograms a patient's own skin cells into iPSCs, which are then differentiated into dopaminergic neuronal precursor cells (DANPCs). These DANPCs are intended to be transplanted back into the patient's brain to restore dopamine production and alleviate Parkinson's symptoms. Aspen's approach leverages genomics and machine learning to evaluate cell quality at every stage of the manufacturing process, aiming to create consistent, reproducible, and scalable GMP-compliant processes.
Target Audience
The primary target audience includes individuals diagnosed with Parkinson's disease who are seeking personalized and regenerative medicine approaches to address neuronal loss and improve motor function.
Features
- Autologous iPSC-derived cell replacement therapy, minimizing the risk of immune rejection
- Personalized cell therapy approach, using cells derived from the patient's own skin cells
- Differentiation of iPSCs into dopaminergic neuronal precursor cells (DANPCs)
- Proprietary genomics platform for evaluating cell quality throughout the manufacturing process
- Machine learning-based genetic tests to ensure cell quality and consistency
- Automated biomanufacturing system for robust and scalable cell production
- GMP-compliant processes to ensure product safety and efficacy